Treatment of Bronchoconstriction in Pneumonia

Pharmacologic Management

The American Thoracic Society recommends inhaled short-acting beta-2 agonists (SABAs) as the first-line treatment for patients with pneumonia experiencing bronchoconstriction, administered via nebulizer or metered-dose inhaler 1, 2
Inhaled short-acting beta-2 agonists (SABAs) should be administered 5-20 minutes before anticipated bronchospasm triggers, providing 2-4 hours of protection 1
For hospitalized patients with pneumonia, nebulized bronchodilators can be delivered with oxygen to maintain oxygen saturation >92% 3, 4
In patients with pre-existing COPD and pneumonia, oxygen therapy should be guided by arterial blood gas measurements to avoid ventilatory failure 3, 4
Monitor for tolerance with daily use of beta-2 agonists, which may reduce duration of protection and prolong recovery time 1
The American College of Allergy, Asthma, and Immunology recommends considering adding inhaled anticholinergics (ipratropium bromide) for additional bronchodilation in patients with pneumonia who have underlying asthma or COPD 5
The American Thoracic Society recommends considering adding inhaled corticosteroids for persistent bronchoconstriction with inflammatory component in patients with pneumonia who have underlying asthma or COPD 1, 2
Systemic corticosteroids may be beneficial for short duration (3-5 days) in severe cases of pneumonia not responding to initial therapy 6
Leukotriene receptor antagonists may be beneficial in patients with exercise-induced bronchoconstriction component 2

Ensure proper hydration to help liquefy secretions in patients with pneumonia 3, 4
Consider using face masks that can promote humidification and prevent water loss in the airways in patients with pneumonia 2
Position patients appropriately to optimize ventilation and drainage of secretions in patients with pneumonia 3
Monitor oxygen saturation, respiratory rate, and other vital signs at least twice daily in hospitalized patients with pneumonia and bronchoconstriction 3, 4
Provide nutritional support, especially in prolonged illness, in patients with pneumonia 3, 4

Bronchoscopy may be valuable to remove retained secretions that contribute to bronchoconstriction in mechanically ventilated patients with pneumonia 3, 4
Patients with COPD and pneumonia may require combination therapy with bronchodilators 7
Monitor closely for ventilatory failure when administering oxygen therapy in patients with COPD and pneumonia 3, 4

Assess response to bronchodilator therapy using objective measures (peak flow, spirometry when available) and clinical parameters in patients with pneumonia 8
Re-evaluate treatment approach if bronchoconstriction persists despite standard therapy in patients with pneumonia 8

Overuse of beta-agonists leading to tolerance and reduced efficacy in patients with pneumonia 1
Inadequate monitoring of oxygen therapy in patients with pre-existing COPD and pneumonia 3, 4